XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation
 9 Months Ended
Oct. 28, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
The stock-based compensation costs that have been charged against income were as follows (in thousands):

13-Weeks Ended39-Weeks Ended
October 28,
2023		October 29,
2022		October 28,
2023		October 29,
2022
Stock-based compensation expense by type:
Stock options
$— $— $220 $155 
Restricted stock units1,112 1,269 4,033 4,881 
Employee stock purchases
92 69 280 304 
Director deferred compensation26 26 79 67 
  Total stock-based compensation expense1,230 1,364 4,612 5,407 
Income tax benefit recognized245 321 1,022 1,247 
  Stock-based compensation expense, net of income tax$985 $1,043 $3,590 $4,160 

Expense for restricted stock units is shown net of forfeitures, which were immaterial for the 13-weeks and 39-weeks ended October 28, 2023 and October 29, 2022.
We granted the following equity awards:
13-Weeks Ended39-Weeks Ended
October 28,
2023		October 29,
2022		October 28,
2023		October 29,
2022
Stock options
— — 8,188 7,212 
Restricted stock unit awards
3,390 1,469 81,905 110,990 
Performance-based restricted stock unit awards
— — 39,567 49,978 
Deferred stock units
553 510 1,708 1,447 

At October 28, 2023, the total compensation cost not yet recognized related to unvested restricted stock unit awards was $6.7 million and the weighted-average period over which such awards are expected to be recognized was 1.8 years. There were no unrecognized compensation costs related to unvested stock options at October 28, 2023.
Details of stock options granted, exercise price per share and the weighted-average grant date fair value were as follows:

13-Weeks Ended39-Weeks Ended
October 28,
2023		October 29,
2022		October 28,
2023		October 29,
2022
Total stock options granted— — 8,188 7,212 
Exercise price$— $— $58.38 $46.22 
Fair value of stock options$— $— $26.87 $21.46 
Under the Hibbett, Inc. Amended and Restated Non-Employee Director Equity Plan, 10,469 shares of our common stock were subject to awards granted during the 39-weeks ended October 28, 2023 and 6,388 shares of our common stock were awarded during the 39-weeks ended October 29, 2022.
The number of shares purchased, the average price per share and the weighted-average grant date fair value of shares purchased through our employee stock purchase plan were as follows:
13-Weeks Ended39-Weeks Ended
October 28,
2023		October 29,
2022		October 28,
2023		October 29,
2022
Shares purchased10,753 6,408 27,484 28,033 
Average price per share$30.85 $38.11 $35.78 $49.30 
Weighted-average fair value at grant date$9.43 $11.41 $13.55 $14.58